SCHEDULE: 5AM Ventures Reports Stake in Artiva Biotherapeutics

5AM Ventures and associated entities have updated their beneficial ownership filing for Artiva Biotherapeutics, Inc., reporting a combined 4.8% stake as of June 30, 2026.

Summary

• This filing is an amendment to a Schedule 13G, reporting changes in beneficial ownership of Artiva Biotherapeutics, Inc. common stock.
• The reporting persons, including 5AM Ventures VI, L.P., 5AM Partners VI, LLC, 5AM Opportunities II, L.P., 5AM Opportunities II (GP), LLC, Andrew J. Schwab, and Kush Parmar, collectively hold a significant stake.
• As of June 30, 2026, the aggregate beneficial ownership reported is 2,353,304 shares, representing 4.8% of the class of securities.
• This ownership is attributed to direct holdings by 5AM Ventures VI, L.P. (1,171,250 shares) and 5AM Opportunities II, L.P. (1,182,054 shares), with shared voting and dispositive power among the related entities and individuals.
• The filing clarifies that the reporting persons expressly disclaim status as a 'group' for the purposes of the Schedule 13G.
• The percentage ownership is based on 24,716,672 shares outstanding as of April 30, 2026, plus shares issued in a public offering on May 11, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily reports on beneficial ownership changes and does not contain new operational or financial performance data.

Positives

• The filing provides clarity on the beneficial ownership structure and holdings of 5AM Ventures and its affiliates in Artiva Biotherapeutics.
• The reporting persons collectively hold a substantial 4.8% stake, indicating significant investor interest.

Negatives

• The filing does not contain any new operational or financial performance data for Artiva Biotherapeutics, Inc.

Risks

• The filing does not explicitly mention any new risks or challenges for Artiva Biotherapeutics, Inc.

Future Outlook

This filing is a Schedule 13G amendment and does not contain forward-looking statements or guidance regarding Artiva Biotherapeutics, Inc.'s future performance.

Management Comments

• The Reporting Persons expressly disclaim status as a 'group' for purposes of this Schedule 13G.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures for institutional investors and significant shareholders, indicating changes in ownership stakes. This filing reflects ongoing investment activity within the biotechnology sector.

Stakeholder Impact

• Shareholders may note the increased or adjusted stake held by 5AM Ventures and its affiliates, which could influence market perception and trading activity.

Next Steps

• The reporting persons will continue to monitor their beneficial ownership in Artiva Biotherapeutics, Inc. and may file further amendments to Schedule 13G as required.

Key Dates

Keywords

beneficial ownership, Schedule 13G, Artiva Biotherapeutics, 5AM Ventures, common stock, investment management, shareholder